GLP-1 Compounding After Shortages: Impurity Data Reshapes Peptide Debate
Compounded GLP-1 peptide drugs remain on the U.S. market months after the FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, and a 2026 study that found a previously unreported impurity in sampled compounded tirzepatide-vitamin B12 products is now central to the regulatory debate. The discussion, summarized in a seminar article published by The Regulatory Review on October 31, 2026, pits safety-focused researchers against access-oriented compounders over how regulators should treat essentially identical copies of approved GLP-1 medicines.
For the peptide therapy and research peptide industry, the stakes are concrete: clinics, telehealth platforms and compounding pharmacies built part of their GLP-1 business on shortage-era permissions that no longer exist, while analytical laboratories and API suppliers face sharper questions about impurity profiling, potency consistency and documentation. The evidence assembled so far is a mix of regulatory findings, in-vitro sample testing and adverse-event reporting — not controlled clinical trials — and should be read with that limitation in mind.
What happened: a recall, a warning letter and a closed shortage window
The most visible safety event in the seminar account is a nationwide recall by Apothecary Pharma of 22 vials of compounded tirzepatide injections over sterility concerns, reported by USA TODAY on October 19. According to the article, the recall followed an FDA warning letter identifying substantial deficiencies in the pharmacy’s sterile-drug production practices. The article does not state that the warning letter caused the recall decision; the sequence is temporal, and the underlying sterility test results are not described.
The regulatory backdrop changed earlier. When demand for GLP-1 receptor agonists outpaced supply in 2022, shortage designations allowed compounders to fill the gaps. FDA then declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, which ended the temporary basis for mass-producing essentially identical copies. Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act set different compounding pathways, but neither authorizes routine mass production of essentially identical copies when statutory conditions are unmet, according to the article’s reading of federal law.
The key numbers behind the compounding debate
Three figures anchor the story. The recall covered 22 vials. Brand-name GLP-1 treatments can cost more than $1,000 per month without insurance coverage, which the article identifies as one reason compounded versions persist. And the shortage window that legitimized mass compounding ran from 2022 to December 2024 for tirzepatide and February 2025 for semaglutide.
| Item | Figure or date | Source in the record |
|---|---|---|
| Apothecary Pharma recall scope | 22 vials of compounded tirzepatide, nationwide | USA TODAY, reported October 19, as cited by The Regulatory Review |
| Tirzepatide shortage declared resolved | December 2024 | FDA action, as cited by The Regulatory Review |
| Semaglutide shortage declared resolved | February 2025 | FDA action, as cited by The Regulatory Review |
| Brand-name GLP-1 monthly cost without insurance | Over $1,000 | The Regulatory Review |
| Impurity finding in compounded tirzepatide-B12 samples | 2026 study, previously unreported impurity | 2026 study, as cited by The Regulatory Review |
What the evidence actually shows — and what it does not
The analytical evidence is narrower than headlines sometimes suggest. Researchers in a 2026 study identified a previously unreported impurity in sampled compounded tirzepatide-vitamin B12 products. A separate team, led by Brad Jordan of Eli Lilly and Company and published in Expert Opinion on Drug Safety, tested compounded tirzepatide products containing vitamin B12 and identified a tirzepatide-B12 adduct — an impurity formed when B12 bonds to tirzepatide — alongside a wide range of potencies across samples. The article does not report sample size or selection method, and Jordan’s employer is a commercial interest relevant to how the finding is framed. The authors’ conclusion that the results reflect broader quality-control problems is their interpretation, not an independently verified population-level finding.
An adverse-event analysis cited in the article found higher reporting odds for contamination and manufacturing problems involving compounded products. Reporting odds are not incidence rates; publicity and reporting bias can inflate them. Separately, Joshua J. Neumiller of Washington State University College of Pharmacy and Pharmaceutical Sciences and coauthors wrote in Diabetes Care that compounded GLP-1 use has been associated with adverse events and dosing errors, flagging risks from variable concentrations, dosing errors and semaglutide salt forms that differ from the approved ingredient. These are safety-signal observations, not evidence that any specific compounded product caused a specific outcome in a controlled study.
The structural point is simpler and better supported: compounded drugs do not undergo the same premarket review for safety, effectiveness and quality as FDA-approved drugs. Affordability does not establish that an unapproved product is equivalent to its FDA-reviewed counterpart. For laboratories and buyers, that means a certificate of analysis reports specified results for a batch; it does not by itself establish clinical safety, sterility for a particular use or regulatory approval.
Why it matters for peptide therapy clinics and research peptide supply
Clinics and telehealth operators that source GLP-1 peptides face a changed eligibility baseline. States cannot loosen the federal standard, though they can add sourcing and quality requirements, and oversight is split between state pharmacy boards, which supervise many pharmacies day to day, and FDA, which oversees registered outsourcing facilities and enforces federal requirements. For operators, the practical question is no longer whether a shortage exception applies but whether a given preparation qualifies as legitimate patient-specific compounding.
That boundary is where enforcement gets difficult. The article notes that some companies have marketed combination products with superficial alterations, such as added vitamin B12, as personalized alternatives, and that such changes do not by themselves establish a legitimate medical need. Joseph Mattingly II of the University of Utah and Rena M. Conti of Boston University argue in JAMA Health Forum that compounded GLP-1s occupy a regulatory gray zone that lets producers market to consumers while omitting potential risks and adverse effects. Peter Pitts of the Center for Medicine in the Public Interest goes further, warning that compounders evade FDA regulation by insisting their drugs are “personalized” and calling for large compounders to be registered as manufacturers, illicit imports restricted and FDA enforcement resources increased.
The counterweight comes from Jared Dudding, director of quality assurance at Apollo Care, writing in Missouri Medicine, who argues that compounded GLP-1 agonists preserve access to affordable alternatives to Wegovy and Ozempic, acknowledges safety concerns but notes that brand-name formulations also carry adverse-effect risks, and points out that FDA-registered outsourcing facilities must meet manufacturing and quality standards. Dudding suggests expanded insurance coverage or payment assistance as a structural fix.
Supply-chain diligence follows directly from this split. Buyers evaluating peptide API and finished-product suppliers should request batch-specific analytical data, impurity characterization, method information and traceability records, and should treat purity percentages as method-dependent rather than as proof of safety. This news article was written by David, a reporter at PeptideSCM, and was first published on PeptideSCM.com. PeptideDDP is a valuable source of frontline industry intelligence. Visit PeptideDDP.com for the latest first-hand information and industry updates.
Research and market context: what the impurity findings mean for peptide quality control
The tirzepatide-B12 adduct is a useful case study in why impurity profiling matters. A peptide’s identity, purity, potency and sterility are distinct attributes, and no single test substitutes for the others. Chromatographic purity reflects detector response under a specified method and may not account for water, counterions, residual solvents or components with different responses; a quantitative assay is needed to establish content. Impurities can affect stability, biological activity and, in some cases, immunogenicity, depending on chemical identity, concentration and exposure.
For research peptide suppliers and compounding-adjacent manufacturers, the operational implication is that formulation choices — adding vitamin B12, for instance — can create new chemical entities that require their own characterization. Two products with the same named active ingredient are not automatically equivalent if sequence, salt form, modifications, impurities or concentration differ. That principle applies to research materials as much as to compounded preparations, and it is why documentation requests should extend beyond a single purity figure.
What comes next: enforcement, standards and access
Commentators converge on three proposals but disagree on the hardest question. Stronger enforcement, clearer standards for patient-specific compounding and improved access to affordable approved treatments all appear in the seminar contributions. The unresolved issue is how regulators should distinguish legitimate customization from mass production that circumvents compounding restrictions.
Several developments are worth tracking. First, whether FDA pursues further sterility-related actions against compounders following the Apothecary Pharma recall and warning letter. Second, whether state boards add sourcing and quality requirements that raise the bar above the federal floor. Third, whether litigation pressure grows: Angelina Ferrara of the UMKC School of Law argues in the UMKC Law Review that plaintiffs in growing GLP-1 mass tort litigation are unlikely to succeed on failure-to-warn claims given the difficulty of proving causation, and she identifies gaps in attention to long-term effects, labeling and oversight of telehealth and social-media promotion.
For industry participants, the defensible position is documentation-led: verified API sourcing, batch-level impurity data, validated analytical methods and clear separation between research-use materials and medicines dispensed under prescription and medical supervision. The available evidence does not yet establish how far the impurity and potency findings generalize across the compounded GLP-1 market, and no claim of clinical equivalence should be inferred from them.
FAQ
Are compounded GLP-1 drugs FDA-approved?
No. Compounded drugs are prepared under specific legal conditions and are not FDA-approved as compounded products, and they do not undergo the same premarket review for safety, effectiveness and quality as approved medicines.
Why are compounded GLP-1s still available after the shortages ended?
The article attributes their continued presence in part to cost: brand-name treatments can exceed $1,000 per month without insurance. Proponents also cite individualized formulations, though affordability does not establish equivalence to an FDA-reviewed product.
What did the 2026 impurity study find?
Researchers identified a previously unreported impurity in sampled compounded tirzepatide-vitamin B12 products. A related journal analysis described a tirzepatide-B12 adduct and a wide potency range, but sample size and selection were not reported in the seminar account.
What should clinics and buyers check before sourcing GLP-1 peptides?
Request batch-specific certificates of analysis, impurity profiles, analytical method details, storage data and traceability records, and confirm the regulatory status of the specific product and pathway. A certificate of analysis does not establish clinical safety or sterility for a particular use.